Four Stories On Tap -- Running Out Of Blogging Time -- More Later -- December 14, 2022

Links only:

• crude oil supply adjustment;
• China healthcare system floundering / foundering due to Covid-19?
• high-tech nuclear plant in Wyoming delayed; can problem be traced back to the Clintons? Posted.
  
• Covid variants: it's too bad this incredibly good article is behind a paywall; 
  

**************************
The Stories

Uranium, Clintons:

• I'm only going to add one link; link here;
• readers that know, know:
• nothing more needs to be said
• posted.
  

Crude oil supply adjustment: 

• "Focus on Fracking" noted this months (years?) ago; it's only getting "worse" -- raising questions about the accuuracy of the weekly EIA petroleum report.
  

China healthcare system floudering / foundering due to Covid-19?

• I think folks forget why "we" originally shut down the economy
  

Covid variants:

• it's too bad this incredibly good article is behind a paywall;

*********************
The Atlantic Story On Covid

The Atlantic story was written before Evusheld was taken off the market. Today, CNBC reported that the FDA took Evushel (Eli Lilly) off the market leaving only one in this sector: bebteloovimab (AstraZeneca).

For the first couple of years of the coronavirus pandemic, the crisis was marked by a succession of variants that pummeled us one at a time.

The original virus rapidly gave way to D614G, before ceding the stage to Alpha, Delta, Omicron, and then Omicron’s many offshoots.

But as our next COVID winter looms, it seems that SARS-CoV-2 may be swapping its lead-antagonist approach for an ensemble cast: Several subvariants are now vying for top billing.

In the United States, BA.5—dominant since the end of spring—is slowly yielding to a slew of its siblings, among them BA.4.6, BF.7, BQ.1, and BQ.1.1; another subvariant, XBB, threatens to steal the spotlight from overseas.

Whether all of these will divvy up infections in the next few months, or whether they’ll be pushed aside by something new, is still anyone’s guess. Either way, the forecast looks a little grim.

None of the new variants will completely circumvent the full set of immune defenses that human bodies, schooled by vaccines or past infections, can launch. Yet all of them seem pretty good at dodging a hefty subset of our existing antibodies.For anyone who gets infected, such evasions could make the difference between asymptomatic and feeling pretty terrible. And for the subset of people who become sick enough to need clinical care, the consequences could get even worse.

Some of our best COVID treatments are made from single antibodies tailored to the virus, which may simply cease to work as SARS-CoV-2 switches up its form.

Past variants have already knocked out several such concoctions—among them, REGEN-COV, sotrovimab, and bamlanivimab/etesevimab—from the U.S. arsenal.

The only two left are bebtelovimab, a treatment for people who have already been infected, and Evusheld, a crucial supplement to vaccination for those who are moderately or severely immunocompromised; both are still deployed in hospitals countrywide.

But should another swarm of variants take over, these two lone antibody therapies could also be obsolete within months, if not weeks.

“It seems like the writing is on the wall,” says Erin McCreary, an infectious-disease pharmacist at the University of Pittsburgh Medical Center. “I live constantly low-key worried that I’m not going to have an active therapy for my patients, and I won’t be able to help them.”

All of this bodes poorly for this winter and beyond. In the near term, millions of immunocompromised people could be left without viable options either to keep SARS-CoV-2 at bay or to temper its blaze once an infection begins to burn. And that loss would set a troubling precedent for seasons to come. The business end of the virus “is now adapting so rapidly that I don’t know how it’s going to be possible for monoclonals to keep up,” says Jeanne Marrazzo, an infectious-disease physician at the University of Alabama at Birmingham. Experts may need to revamp the strategies they use to bring new therapies to market—or find themselves, once again, in a serious bind.

“I worry,” Marrazzo told me, “that we’re on a razor’s edge.”